Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 4Phase 4 2Phase 3 2Phase 2/3 1Phase 1/2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 16Breast 6Gynecologic 3Tumor-Agnostic 2NET 2Head & Neck 2Endocrine 2Other solid neoplasm 1CNS 1

Conditions

Neuroendocrine Tumors 2Lung Neoplasms 1Carcinoma, Large Cell 1

Interventions

lanreotide 5Octreotide 5Everolimus 4Dexmedetomidine 3Cabergoline 3pasireotide 2Phenoxybenzamine 2Carboplatin 2trametinib 1testosterone enanthate 1surufatinib 1selpercatinib 1pralsetinib 1pegvisomant 1lutetium Lu 177 dotatate 1lenvatinib 1larotrectinib 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1gadobutrol 1gadobenic acid 1entrectinib 1dabrafenib 1candesartan 1arginyllysine 1anlotinib 1Vitamin D 1Trimethoprim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Carboplatin × Endocrine × Clear all
NCT06485739 2024-07-03

Irinotecan Liposomes for the Treatment of Neuroendocrine Carcinoma

First Affiliated Hospital Xi'an Jiaotong University

Phase 4 Not yet recruiting
20 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT01317615 2016-03-30

RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation

Novartis

Phase 4 Completed
49 enrolled 11 charts
EndocrineNETThoracic

Lung Neoplasms, Carcinoma, Large Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡